ArticleBMC microbiology2025
Biotechnological potential and genomic analysis of the Leuconostoc mesenteroides F17 and F18 strains isolated from camel milk.
Article in BMC microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Camel milk is known for its distinctive nutritional and antimicrobial properties. Thus, it offers a valuable niche for discovering novel probiotic strains with potential health benefits. In this context, two Leuconostoc mesenteroides strains, F17 and F18 were isolated from this dairy matrix and their properties analysed. Also, to gain deeper insight into their probiotic and technological traits, the sequencing of the whole genomes of both strains was conducted, revealing key genetic features supporting their suitability as starter cultures. The two bacteria displayed desirable technological properties including among them rapid milk acidification capability as well as proteolytic and lipolytic activities. F17 and F18 produced riboflavin (0.11 and 0.15 mg/L) and exopolysaccharides (1.8 g/L and 3.7 g/L) characterized as dextran by physicochemical analysis. The F17 and F18 DsrD dextransucrases of ~ 170 kDa, responsible for the dextran synthesis, were visualized by a zymogram analysis and their dsrD coding genes, with 98.99% identity, were identified in their genomes. After 24 h growth in a sucrose-containing medium, analysis of metabolic fluxes in culture supernatants of both bacteria demonstrated accumulation of the sweetener mannitol and the antimicrobial lactic acid; at the levels of 59 mM and 76.57 mM in the case of the best performer (F18). Furthermore, the results demonstrated that both strains exhibited good survival rates under in vitro simulated stomach duodenum-passage. A high surface adhesion was also observed for F17 and F18 including hydrophobicity of 30.15% and 31.72% and auto-aggregation ability of 44.71% and 53.23%, with a good resistance to phenol exposure and to moderated heat shock. As expected from the genomes inspection, the safety analysis revealed that the two strains were susceptible to most of the tested antibiotics, and none of them showed any hemolytic activity or biogenic amines synthesis capability. Both cultures supernatants exhibited significant growth inhibition of foodborne pathogens, presumably due to the present of lactic acid. Thus, these findings suggest that camel milk may harbor lactic acid bacteria with promising technological and probiotic traits, as exemplified by F17 and F18.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.